Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effective dose of remimazolam + low-dose esketamine for inhibiting gastroscope insertion reaction
ChiCTR2200058749Phase 4Completed
- Sponsor
- Zhuji People's Hospital of Zhejiang Province
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of remimazolam and esketamine in anxiety disorder and procedural discomfort, sponsored by Zhuji People's Hospital of Zhejiang Province. Primary endpoint: ED50. Started May 2022; status: completed.
02
Drugs
remimazolamesketamine
03
Conditions
anxiety disorderprocedural discomfort
Beyond the preview
Go deeper on ChiCTR2200058749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200058749.